Findings

What do systematic reviews say?

6 questions · 7 findings · 2 reviews · Oral Health

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 7 · 100%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Epidermal growth factor vs placebo

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Epidermal growth factor led to lower oral mucositis (moderate to severe) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.67 [0.45, 0.99]
1 study · 103 participants
GRADE not reported

Epidermal growth factor (EGF), oral spray vs placebo

Oral mucositis (severe) · Adults with cancer receiving treatment

Epidermal growth factor (EGF), oral spray showed no clear difference in oral mucositis (severe) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
Chemoradiotherapy to the head and neck
RR 1.03 [0.59, 1.80]
1 study · 136 participants
GRADE not reported

Epidermal growth factor (EGF), oral spray vs placebo

Oral mucositis (moderate to severe) · Adults with cancer receiving treatment

Epidermal growth factor (EGF), oral spray showed no clear difference in oral mucositis (moderate to severe) compared with placebo; GRADE not reported.

2 findings from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
Chemoradiotherapy to the head and neck
RR 1.06 [0.78, 1.43]
1 study · 136 participants
GRADE not reported
Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
Radiotherapy to the head and neck
RR 0.67 [0.45, 0.99]
1 study · 103 participants
GRADE not reported

Epidermal growth factor (EGF), oral spray vs placebo

Adverse events · Adults with cancer receiving treatment

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
Adverse events narratively reported; no serious events attributed to EGF (not GRADE-rated)
2 studies
GRADE not reported

Epidermal growth factor (EGF), oral spray vs placebo

Interruptions to cancer treatment (radiotherapy breaks longer than two days) · Adults with cancer receiving treatment

Epidermal growth factor (EGF), oral spray showed no clear difference in interruptions to cancer treatment (radiotherapy breaks longer than… compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
Radiotherapy to the head and neck
RR 4.38 [0.25, 75.44]
1 study · 113 participants
GRADE not reported

Epidermal growth factor (EGF), oral spray vs placebo

Normalcy of diet (total parenteral nutrition) · Adults with cancer receiving treatment

Epidermal growth factor (EGF), oral spray showed no clear difference in normalcy of diet (total parenteral nutrition) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
Chemoradiotherapy to the head and neck
RR 1.03 [0.55, 1.94]
1 study · 136 participants
GRADE not reported